Login to Your Account

Other News To Note

Wednesday, April 11, 2012

• KineMed Inc., of Emeryville, Calif., received a Rapid Access to Intervention Development (RAID) grant from the National Institutes of Health for manufacturing, formulation and investigational new drug-enabling safety studies of FX-5A, an ApoA-I mimetic designed to reverse atherosclerosis and heart disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription